NCT05042206View on ClinicalTrials.gov

Clinical Trial to Evaluate Safety of Allogeneic Bone Marrow Derived Mesenchymal Stem Cell in Chronic Kidney Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

November 24, 2021

Primary Completion Date

September 21, 2023

Study Completion Date

September 21, 2023

Conditions
Chronic Kidney Disease Stage 3BChronic Kidney Disease stage4
Interventions
BIOLOGICAL

Cellgram-CKD

Allogeneic bone marrow-derived mesenchymal stem cell therapy for the treatment of chronic kidney disease

Trial Locations (1)

Unknown

Asan Medical Center, Seoul

All Listed Sponsors
lead

Pharmicell Co., Ltd.

INDUSTRY

NCT05042206 - Clinical Trial to Evaluate Safety of Allogeneic Bone Marrow Derived Mesenchymal Stem Cell in Chronic Kidney Disease | Biotech Hunter | Biotech Hunter